SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cell Therapeutics (CTIC) -- Ignore unavailable to you. Want to Upgrade?

To: D.Lu who wrote (414)2/16/2005 9:59:07 AM
From: tom pope  Respond to of 946
 
I was about to ask Erik the same question. It sounds pretty dire to me, unless it is old news.



To: D.Lu who wrote (414)2/16/2005 10:02:12 AM
From: Icebrg  Read Replies (1) | Respond to of 946
 
I don't think the markets are aware of these results yet. The abstract just appeared at PubMed.

One has to ask how relevant they are. In the Stellar trials a lower dose is used.

But the report is interesting, as it indicates there seems to be a definite limit with regard to how much Xyotax that can be administered.

Erik


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News